Bisphosphonates

$5K Bisphosphonate Fine for Sadler

Trainer John Sadler has been fined $5,000 by the Del Mar stewards, and has entered into a settlement agreement and mutual release with the California Horse Racing Board (CHRB), for "knowingly" bringing a horse into a CHRB enclosure "that had been administered bisphosphonates within previous six months," according to a ruling Friday. The horse in question--as first reported by the BloodHorse--was GISW sprinter Flagstaff (Speightstown), who was recently retired at the age of seven. Flagstaff tested positive for the bisphosphonate "clodronate" after finishing second in the 2020 GII Santa Anita...

[ Read More ]
Bisphosphonate Complaint Against Metz Dismissed

A complaint against trainer Jeff Metz regarding a positive bisphosphonate test from last year was dismissed during a closed session vote of the California Horse Racing Board commissioners Sept. 15. According to a release from the CHRB, the board believed it would be unfair to punish Metz for the positive test of his trainee, Camino de Estrella, because testing and a subsequent investigation revealed that the substance had been administered in 2018--well before the horse was in Metz's care. The Maddy Laboratory at UC Davis detected the presence of Tiludronic...

[ Read More ]
Bisphosphonate Complaint Issued Against Metz By CHRB

A complaint involving a banned bisphosphonate has been lodged by the California Horse Racing Board (CHRB) against trainer Jeffrey Metz, summoning him to a stewards' hearing. According to a CHRB complaint dated Apr. 29, a positive for tiludronic acid was confirmed via split-sample testing from Camino de Estrella (Mineshaft), who finished sixth in the third race Sept. 27, 2020, at Santa Anita. The now-7-year-old gelding was claimed that day for $20,000, and has finished no better than sixth in four subsequent starts for a four-way partnership that includes trainer Bill...

[ Read More ]
TERF Awards $20k to the University Of Pennsylvania School Of Veterinary Medicine

The Thoroughbred Education and Research Foundation (TERF) has awarded $20,000 to the University Of Pennsylvania School Of Veterinary Medicine to be used for equine research. In alignment with their mission to support and promote equine research, TERF annually provides grant funding to organizations that are engaged in the research of issues which impact equine health. Funding will be used to support research by Mary Robinson, VMD, PhD in a study of the use of bisphosphonates to medically treat equines. Bisphosphonates inhibit bone breakdown and are useful for treating bone disorders...

[ Read More ]
CHRB Bisphosphonates Rule Effective July 1
CHRB Bisphosphonates Rule Effective July 1

The California Horse Racing Board's Rule 1867.1, which becomes effective July 1, prohibits the administration of bisphosphonates to any horse within a facility regulated by the CHRB and also prohibits any horse from entering the grounds that has been administered the drug within six months. This means that any horse administered bisphosphonates since Jan. 1, 2020, will not be permitted within any CHRB-regulated facility (racetracks and training centers) within a six-month period of such administration. Additional information on bisphosphonate use in race horses is available on the CHRB website (www.chrb.ca.gov)...

[ Read More ]
St. Elias To Fund Research on Bisphosphonates

Vinnie and Teresa Viola's St. Elias Stables will sponsor a research project to help develop alternate methods for detection of bisphosphonates in Thoroughbreds, the Grayson-Jockey Club Research Foundation announced today. This gift was made following an appeal by Grayson, the Racing Medication & Testing Consortium (RMTC), and the American Association of Equine Practitioners in June 2019 for research proposals to investigate bisphosphonate administration in racehorses and in young racing prospects intended for sale at public auction. This research will be based at the University of California-Davis K.L. Maddy Equine Pharmacology...

[ Read More ]
UPenn Researchers Launching Study On Lasix, Bisphosphonates' Impact On Catastrophic Injuries

Researchers at the University of Pennsylvania's School of Veterinary Medicine are launching a novel study exploring possible effects resulting from the combined use of furosemide, commonly known as Lasix, and bisphosphonates in equine athletes. Led by Dr. Mary Robinson, assistant professor of veterinary pharmacology and director of the Equine Pharmacology Laboratory at Penn Vet's New Bolton Center, the study is poised to be the first comprehensive analysis of the two drugs that, when used concurrently, could be capable of diminishing bone integrity and compromising cardiac function in racehorses. "The beauty...

[ Read More ]
X

Never miss another story from the TDN

Click Here to sign up for a free subscription.